Amneal and Metsera partner on obesity drug portfolio; new India facilities cost $150-200M

Amneal Pharmaceuticals, Inc.

Amneal to build two manufacturing facilities in India for peptide synthesis and sterile fill-finish; net cost $150-200M over 4-5 years.
Amneal named Metsera's preferred supply partner for US and Europe; licensed to commercialize in select emerging markets.
Metsera's lead candidate MET-097 (GLP-1 injectable) showed durable weight loss in Phase 1; expected first drug under collaboration.
Collaboration leverages Amneal's existing manufacturing network and provides a new high-growth vector in the obesity market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.